Physician profile
David E Beal
NPI 1508536616
$3,223.29
in general payments reported to CMS, 2019-2025
29 companies · $1,005 in 2025
The $1,005 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,023 · 2024: $1,195 · 2025: $1,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,184 · Education: $39.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,183.72 |
| Education | $39.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $575.41 | 2023-2025 | Repatha, Evenity, Otezla |
| Shield Therapeutics INC | $382.97 | 2023-2025 | Accrufer |
| Novo Nordisk INC | $378.27 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $261.15 | 2023-2025 | |
| Lilly USA, LLC | $211.68 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Regeneron Healthcare Solutions, INC. | $178.29 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $170.11 | 2023-2025 | Arexvy, Shingrix, Bexsero |
| Merck Sharp & Dohme LLC | $149.81 | 2023-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Axsome Therapeutics, INC. | $119.18 | 2025 | Symbravo |
| Abbvie INC. | $119.09 | 2023-2025 | |
| Pfizer INC. | $83.32 | 2024-2025 | |
| Genzyme Corporation | $75.34 | 2023-2025 | |
| Hologic Sales and Service, LLC | $75.01 | 2024-2025 | Thinprep 2000 Processor, Aptima, Affirm Prone Biopsy System |
| Astrazeneca Pharmaceuticals LP | $65.55 | 2023 | Breztri, Tezspire |
| Dexcom, INC. | $62.63 | 2023-2025 | Dexcom G6 Transmitter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $47.89 | 2023 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $46.34 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.52 | 2025 | |
| Organon LLC | $27.73 | 2024 | |
| Redhill Biopharma INC. | $20.44 | 2025 | Talicia |
| Sanofi Pasteur INC. | $18.87 | 2025 | |
| Phadia US INC. | $16.90 | 2024 | Immunocap |
| Ardelyx, INC. | $16.28 | 2024 | Ibsrela |
| Agile Therapeutics, INC. | $14.73 | 2023 | Twirla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.41 | 2024 | Xifaxan, Trulance |
| Scilex Pharmaceuticals INC. | $14.37 | 2024 | |
| Novartis Pharmaceuticals Corporation | $13.41 | 2024 | |
| Phathom Pharmaceuticals, INC. | $13.40 | 2024 | Voquezna |
| Coopersurgical, INC. | $13.19 | 2023 | Paragard T 380a |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Beal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.